Literature DB >> 19594383

The influence of enrollment criteria on recruitment and outcome distribution in traumatic brain injury studies: results from the impact study.

Bob Roozenbeek1, Andrew I R Maas, Anthony Marmarou, Isabella Butcher, Hester F Lingsma, Juan Lu, Gillian S McHugh, Gordon D Murray, Ewout W Steyerberg.   

Abstract

Substantial heterogeneity exists among patients who suffer from traumatic brain injury (TBI). Strict enrollment criteria may diminish heterogeneity in randomized controlled trials (RCTs), but will also decrease recruitment and may affect the outcome distribution. The aim of this study was to investigate the influences of commonly used enrollment criteria for RCTs in TBI on potential recruitment and on outcome distribution. We used individual patient data from the International Mission on Prognosis and Analysis of Clinical Trials in TBI (IMPACT) database, including six therapeutic phase III RCTs (n = 5816) and three surveys (n = 2217) in TBI. The primary outcome was the Glasgow Outcome Scale (GOS) at 6 months after injury, which we dichotomized as favorable/unfavorable. We investigated the influences of commonly used enrollment criteria on recruitment and outcome distribution: time window between injury and admission to study hospital <or= 8 h; age at injury <or= 65 years; >or= 1 reactive pupil; motor score > 1; Glasgow Coma Scale <or= 8. Application of all enrollment criteria resulted in a large reduction of recruitment in both the surveys (up to 65%) and the RCTs (up to 41%). Among the remaining patients, fewer had an unfavorable outcome in both the surveys (original, 60%; remaining, 44%) and the RCTs (original, 43%; remaining, 38%). Applying these enrollment criteria to patients from the surveys resulted in an outcome distribution that approximated the outcome observed in the RCTs. The use of strict enrollment criteria leads to substantial reductions in the recruitment of RCTs in TBI. The outcome in TBI studies depends strongly on the enrollment criteria.

Entities:  

Mesh:

Year:  2009        PMID: 19594383      PMCID: PMC2989840          DOI: 10.1089/neu.2008.0569

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  14 in total

Review 1.  Design and statistical issues in multicenter trials of severe head injury.

Authors:  S C Choi; R Bullock
Journal:  Neurol Res       Date:  2001 Mar-Apr       Impact factor: 2.448

2.  Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months.

Authors:  Phil Edwards; Miguel Arango; Laura Balica; Rowland Cottingham; Hesham El-Sayed; Barbara Farrell; Janice Fernandes; Tamar Gogichaisvili; Nyoman Golden; Bennie Hartzenberg; Mazhar Husain; Mario Izurieta Ulloa; Zouheir Jerbi; Hussein Khamis; Edward Komolafe; Véronique Laloë; Gabrielle Lomas; Silke Ludwig; Guy Mazairac; Maria de los Angeles Muñoz Sanchéz; Luis Nasi; Fatos Olldashi; Patrick Plunkett; Ian Roberts; Peter Sandercock; Haleema Shakur; Caridad Soler; Reto Stocker; Petr Svoboda; Stefan Trenkler; N K Venkataramana; Jonathan Wasserberg; David Yates; Surakrant Yutthakasemsunt
Journal:  Lancet       Date:  2005 Jun 4-10       Impact factor: 79.321

3.  Predicting outcome after traumatic brain injury: development and validation of a prognostic score based on admission characteristics.

Authors:  Chantal W P M Hukkelhoven; Ewout W Steyerberg; J Dik F Habbema; Elana Farace; Anthony Marmarou; Gordon D Murray; Lawrence F Marshall; Andrew I R Maas
Journal:  J Neurotrauma       Date:  2005-10       Impact factor: 5.269

4.  Adjustment for strong predictors of outcome in traumatic brain injury trials: 25% reduction in sample size requirements in the IMPACT study.

Authors:  Adrián V Hernández; Ewout W Steyerberg; Isabella Butcher; Nino Mushkudiani; Gillian S Taylor; Gordon D Murray; Anthony Marmarou; Sung C Choi; Juan Lu; J Dik F Habbema; Andrew I R Maas
Journal:  J Neurotrauma       Date:  2006-09       Impact factor: 5.269

5.  Evaluation of designs for clinical trials of neuroprotective agents in head injury. European Brain Injury Consortium.

Authors:  S G Machado; G D Murray; G M Teasdale
Journal:  J Neurotrauma       Date:  1999-12       Impact factor: 5.269

Review 6.  Prognosis and clinical trial design in traumatic brain injury: the IMPACT study.

Authors:  Andrew I R Maas; Anthony Marmarou; Gordon D Murray; Sir Graham M Teasdale; Ewout W Steyerberg
Journal:  J Neurotrauma       Date:  2007-02       Impact factor: 5.269

Review 7.  Ethical considerations on consent procedures for emergency research in severe and moderate traumatic brain injury.

Authors:  E J O Kompanje; A I R Maas; M T Hilhorst; F J A Slieker; G M Teasdale
Journal:  Acta Neurochir (Wien)       Date:  2005-04-07       Impact factor: 2.216

8.  Some prognostic models for traumatic brain injury were not valid.

Authors:  Chantal W P M Hukkelhoven; Anneke J J Rampen; Andrew I R Maas; Elana Farace; J Dik F Habbema; Anthony Marmarou; Lawrence F Marshall; Gordon D Murray; Ewout W Steyerberg
Journal:  J Clin Epidemiol       Date:  2006-02       Impact factor: 6.437

9.  Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations

Authors: 
Journal:  Neurosurgery       Date:  1999-06       Impact factor: 4.654

10.  A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury.

Authors:  L F Marshall; A I Maas; S B Marshall; A Bricolo; M Fearnside; F Iannotti; M R Klauber; J Lagarrigue; R Lobato; L Persson; J D Pickard; J Piek; F Servadei; G N Wellis; G F Morris; E D Means; B Musch
Journal:  J Neurosurg       Date:  1998-10       Impact factor: 5.115

View more
  6 in total

1.  New considerations in the design of clinical trials for traumatic brain injury.

Authors:  Bob Roozenbeek; Hester F Lingsma; Andrew Ir Maas
Journal:  Clin Investig (Lond)       Date:  2012-02

2.  Application of a TEG-Platelet Mapping Algorithm to Guide Reversal of Antiplatelet Agents in Adults with Mild-to-Moderate Traumatic Brain Injury: An Observational Pilot Study.

Authors:  Svetlana Kvint; Alexis Gutierrez; Anya Venezia; Eileen Maloney; James Schuster; Monisha A Kumar
Journal:  Neurocrit Care       Date:  2022-06-16       Impact factor: 3.210

Review 3.  Detailed systematic analysis of recruitment strategies in randomised controlled trials in patients with an unscheduled admission to hospital.

Authors:  Ceri Rowlands; Leila Rooshenas; Katherine Fairhurst; Jonathan Rees; Carrol Gamble; Jane M Blazeby
Journal:  BMJ Open       Date:  2018-02-02       Impact factor: 2.692

Review 4.  Neuroprotection in Traumatic Brain Injury: Mesenchymal Stromal Cells can Potentially Overcome Some Limitations of Previous Clinical Trials.

Authors:  Marco Carbonara; Francesca Fossi; Tommaso Zoerle; Fabrizio Ortolano; Federico Moro; Francesca Pischiutta; Elisa R Zanier; Nino Stocchetti
Journal:  Front Neurol       Date:  2018-10-24       Impact factor: 4.003

5.  Efficacy and safety of erythropoietin for traumatic brain injury.

Authors:  Motao Liu; Amy J Wang; Yu Chen; Gexin Zhao; Zhifeng Jiang; Xinbang Wang; Dongliang Shi; Tiansong Zhang; Bomin Sun; Hua He; Ziv Williams; Kejia Hu
Journal:  BMC Neurol       Date:  2020-11-02       Impact factor: 2.474

6.  Advancing care for traumatic brain injury: findings from the IMPACT studies and perspectives on future research.

Authors:  Andrew I R Maas; Gordon D Murray; Bob Roozenbeek; Hester F Lingsma; Isabella Butcher; Gillian S McHugh; James Weir; Juan Lu; Ewout W Steyerberg
Journal:  Lancet Neurol       Date:  2013-10-17       Impact factor: 44.182

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.